NCT07528898 2026-04-14
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT07391774 2026-04-13
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
National Cancer Institute (NCI)
Phase 3 Not yet recruiting
NCT07378306 2026-01-30
FACT-TN
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07372079 2026-01-28
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07187752 2025-09-23
Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes
Shandong Cancer Hospital and Institute
Phase NA Not yet recruiting
NCT07161791 2025-09-09
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer
Harbin Medical University
Phase 1/2 Not yet recruiting
NCT07101614 2025-08-03
A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
Shengjing Hospital
Phase 2 Not yet recruiting
NCT07005557 2025-06-05
SENIOR
Fudan University
Phase 3 Not yet recruiting
NCT06691594 2025-02-20
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06746870 2024-12-24
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 2 Not yet recruiting
NCT06438055 2024-05-31
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
Tianjin Medical University Cancer Institute and Hospital
Phase NA Not yet recruiting
NCT05862610 2023-07-24
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT04736589 2021-02-03
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College
Phase 3 Not yet recruiting